Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Blood Neoplasia|December 24, 2025
Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockadeReid W Merryman, Justin Kline, Robert A Redd, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|July 24, 2025
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell LymphomaNira Krasnow, Katie Maurer, Catherine Jiawen Song, et al.
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2020
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and ToxicityCaron A Jacobson, Bradley D Hunter, Robert Redd, et al.
Pageof 14